HMGA2 Gene rs8756 A>C Polymorphism Reduces Neuroblastoma Risk in Chinese Children: A Four-Center Case-Control Study

Background: Neuroblastoma, mainly affecting children, is a lethal malignancy arising from the developing sympathetic nervous system. The genetic etiology of neuroblastoma remains mostly obscure. High mobility group AT-hook 2 (HMGA2), an oncogenic gene, is up-regulated in many tumors. Single nucleotide polymorphisms (SNPs) often modify cancer susceptibility. However, no studies are investigating the association between HMGA2 SNPs and neuroblastoma susceptibility.

Methods: We conducted a four-center case-control study to evaluate the association between three HMGA2 polymorphisms (rs6581658 A>G, rs8756 A>C and rs968697 T>C) and neuroblastoma susceptibility in a Chinese population with 505 cases and 1070 controls. Logistic regression was performed to evaluate the strength of the association.

Results: We found that the rs8756 AC/CC genotypes were associated with a reduced neuroblastoma risk when compared to rs8756 AA genotype [Adjusted odds ratio (OR) =0.74, 95% confidence interval (CI)=0.56–0.99, P=0.039]. Carriers with 3 protective genotypes have lower neuroblastoma susceptibility than those without or with 0–2 protective genotypes. The stratified analysis revealed that the protective effects of rs8756 AC/CC genotypes were more predominant among children of age >18 months, males, and subgroups with the tumor in the mediastium. Furthermore, haplotype analysis uncovered that haplotype ACC significantly reduced neuroblastoma risk.

Conclusion: Our study indicated HMGA2 rs8756 A>C polymorphism is significantly associated with decreased neuroblastoma risk.

Keywords: neuroblastoma, susceptibility, HMGA2, polymorphism

Introduction

Neuroblastoma is one of the most common pediatric extracranial solid tumors, which is derived from primordial sympathetic neural precursors. The incidence of neuroblastoma is approximately 1/7000 in the USA2,4 and 1/13,000 in China.3,4 It is the third leading cause of tumor-related death in children, accounting for 15% of all cases.5,6 Neuroblastoma is a highly heterogeneous disorder characterized by diverse clinical symptoms. For instance, most of the low-risk patients have spontaneous regression without chemotherapy.7 However, high-risk patients, constituting near 50% of neuroblastoma, have widely disseminated disease at diagnosis and have survival rates of less than 40% despite intensive therapies.8 Moreover, the lifelong serious co-existing health issues often affect survivors’ social life, including marriage and employment.9 Therefore, neuroblastoma remains a great burden for affected families and public health.10
The pathogenesis of neuroblastoma is not fully understood. Approximately 1–2% of neuroblastoma cases are familial,\(^1\) which was reported to associate with the mutation of \textit{PHOX2B}\(^2\) and \textit{ALK}\(^3\) genes. Sporadic neuroblastoma is the primary form of neuroblastoma. Environmental factors such as radiation sources, wood dust, and hydrocarbons\(^4,5\) have been thought to predispose individuals to neuroblastoma. However, not all offspring of exposed parents develop neuroblastoma.\(^6\) It suggests that genetic factors may play a role in the occurrence of neuroblastoma. Increasing evidence indicates that the genetic polymorphisms may somehow contribute to the neuroblastoma susceptibility.\(^7-9\)

Genome-wide association study (GWAS) has shed more light on the genetic etiology of human diseases including cancers.\(^10\) It now is a powerful tool to study the genetic mechanisms of neuroblastoma. To date, six neuroblastoma GWASs have been performed and several inherited common variants in susceptibility genes were identified. \textit{CASC15} was the first variant discovered to predispose to neuroblastoma by Maris et al in 2008.\(^\text{11} 11\) Later on, the same group found that several common variants in \textit{BARD1} gene\(^\text{12} 12\) were related to high-risk neuroblastoma; moreover, the polymorphisms within \textit{DUSP12}, \textit{DXS4}, \textit{IL31RA}, and \textit{HSD17B12} contributed to the low-risk neuroblastoma.\(^\text{13} 13\) In 2011, Wang et al demonstrated that single nucleotide polymorphisms (SNPs) in the \textit{LMO1} gene could modify the neuroblastoma susceptibility.\(^\text{14} 14\) Diskin et al indicated that the polymorphisms in \textit{LIN28B} and \textit{HACE1} genes also altered susceptibility to neuroblastoma.\(^\text{15} 15\) More recent GWAS performed by McDaniel et al revealed that common variants within the \textit{CPZ} gene at 4p16 and upstream of the \textit{MLF1} gene at 3q25 could modify neuroblastoma susceptibility.\(^\text{16} 16\) More importantly, the GWAS results are very useful in discovering novel biological processes underlying the malignant transformation of neuroblastoma. For example, Cimmino et al performed a fine-mapping analysis of \textit{BARD1} locus (2q35) using GWAS data from 556 high-risk neuroblastoma patients and 2575 controls of European-American ancestry recently. They identified a potentially causative SNP rs17489363 C>T in the canonical promoter region that associated with high-risk neuroblastoma. They demonstrated that the risk allele T of rs17489363 altered binding sites of the transcription factor \textit{HSF1} and lead to low expression of full-length \textit{BARD1} mRNA and protein, and the decreased expression of full-length \textit{BARD1} might contribute to neuroblastoma progression through promoting cell proliferation and invasion, the full-length \textit{BARD1} may function as a tumor suppressor.\(^\text{17} 17\)

Furthermore, candidate gene approaches also discovered \textit{NEFL}\(^\text{18} 18\) and \textit{CDKN1B}\(^\text{19} 19\) gene polymorphisms could influence neuroblastoma susceptibility.

Epithelial-to-mesenchymal transition (EMT) is a critical step in the progression of cancer.\(^20\) EMT confers cancer cells specific mesenchymal characteristics, such as increased cell motility, resistance to apoptosis, and resistance to therapy.\(^21\) The high mobility group AT-hook 2 (\textit{HMGA2}), located in chromosome 12q13-15, has been involved in the EMT.\(^22\) The \textit{HMGA2} is a member of the high motility group (HM) protein family and abundantly expressed in the undifferentiated mesenchymal tissues.\(^23\) One AT-hook basic domain in \textit{HMGA2} binds to DNA minor groove at sequences abundant with A and T nucleotides, which helps to install transcriptional or enhancer complexes on chromatin.\(^24\) Furthermore, \textit{HMGA2} functions as a transcription co-regulator by recruiting other transcription-associated proteins.\(^25\) Apart from EMT, \textit{HMGA2} also regulates cell proliferation and differentiation, overexpression of which is observed in numerous human tumor tissues. Sarhadi et al reported that intense \textit{HMGA2} expression contributed to the metastasis and poor prognosis in lung cancer.\(^26\) Elevated \textit{HMGA2} expression promoted metastasis and drug resistance in gastrointestinal tumors.\(^27,28\) Up-regulation of \textit{HMGA2} often results from genetic alterations such as gene amplification and translocation. Besides, previous researches showed that some SNPs in genes are able to influence the gene expression and protein structure. There are some studies to evaluate the association between SNPs in the \textit{HMGA2} gene and complex human diseases, such as childhood and adult height,\(^29\) bone mineral density,\(^30\) and nephropathy.\(^31\) However, there are no publications regarding the association between \textit{HMGA2} gene polymorphisms and cancer susceptibility, including neuroblastoma. Therefore, we performed this four-center case-control study to evaluate the association between SNPs in the \textit{HMGA2} gene and neuroblastoma susceptibility in Chinese children.

**Materials and Methods**

**Study Subjects**

In total, the current study included 505 clinically and histopathologically diagnosed neuroblastoma cases and 1070 cancer-free controls.\(^32\) As described previously, participants were recruited from four centers of China: Guangzhou Women and Children’s Medical Center, The First Affiliated Hospital of Zhengzhou University, The Second Affiliated Hospital, and Yuying Children’s Hospital of Wenzhou Medical University, and the Second Affiliated...
Hospital of Xi’an Jiaotong University. The eligibility criteria for the included subjects were described previously. Written informed consent was acquired before the study from all participants or their parents. And the study protocols were ratified by the Institutional Review Board of each participating institution. This study was conducted in accordance with the Declaration of Helsinki.

**Polymorphism Selection and Genotyping**

We searched for potentially functional HMGA2 polymorphisms in the dbSNP database (https://www.ncbi.nlm.nih.gov/snp/) and SNPInfo (https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html) using the selection criteria described in the previous publication. Three polymorphisms in the HMGA2 gene were ultimately selected. The rs8756 A>C, located in 3’ untranslated region (UTR) of the HMGA2 gene, may affect the microRNA binding affinity, and thereby influence the expression and stabilization of the HMGA2 gene. The rs6581658 A>G and rs968697 T>C, located in the 5’ near gene region, may affect the binding of transcription factors and the transcription of the HMGA2 gene. As showed in **Supplemental Figure 1**, there was no significant linkage disequilibrium (R²<0.8) among these three included SNPs (R²=0.001 between rs6581658 and rs968697; R²=0.008 between rs6581658 and rs8756; R²=0.001 between rs968697 and rs8756).

For genotyping, the genomic DNA was purified from venous blood of participants by a TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd., Beijing, China) and genotyped following the standard TaqMan real-time PCR methods. To assure the authenticity of the result, 10% of the samples were selected randomly to perform a second-time analysis. All repeated samples obtained a 100% concordance.

**Statistical Analysis**

Whether the selected polymorphisms were in Hardy-Weinberg equilibrium (HWE) in all control was assessed by the goodness-of-fit χ² test. And the distributions of demographics and allele frequencies between all cases and controls were compared through a two-sided chi-square test. A logistic regression analysis was conducted. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the association between the HMGA2 polymorphisms and neuroblastoma risk. Moreover, stratified analysis was also carried out regarding age, gender, tumor origin site, and clinical stage. All statistical analyses were conducted using SAS software (version 9.4 SAS Institute, NC, USA). And a result was thought to be statistically significant when the P value < 0.05.

**Results**

**Associations Between HMGA2 Polymorphisms and Neuroblastoma Risk**

In the current case-control study, 505 cases and 1070 controls were successfully genotyped (Supplemental Table 1). The genotype frequencies distribution of three selected SNPs were in accordance with HWE among the controls (P=0.365 for rs6581658 A>G, P=0.811 for rs8756 A>C and P=0.780 for rs968697 T>C). The genotype frequencies of the SNPs in neuroblastoma cases and cancer-free controls were shown in Table 1. In single locus analysis, the rs8756 A>C was associated with decreased neuroblastoma susceptibility; carriers with rs8756 AC/CC genotypes had significantly reduced neuroblastoma risk when compared with subjects with AA genotype [Adjusted OR (AOR)=0.74, 95% CI=0.56–0.99, P=0.039]. We further evaluated the combined effect of protective genotypes of HMGA2 on neuroblastoma risk. The results showed that individuals carrying 3 protective genotypes were at significantly lower risk of developing neuroblastoma than those without protective genotypes (AOR=0.33, 95% CI=0.13–0.84, P=0.020) and those with 0–2 protective genotypes (AOR=0.35, 95% CI=0.18–0.70, P=0.003).

**Stratification Analysis**

We investigated the effects of rs8756 A>C polymorphism and combined protective genotypes on the neuroblastoma risk among different subgroups defined by age, gender, site of tumor origin, and clinical stage. As shown in Table 2, the rs8756 AC/CC genotypes were significantly associated with decreased neuroblastoma risk in children older than 18 months (AOR=0.65, 95% CI=0.45–0.93, P=0.020), male (AOR=0.63, 95% CI=0.43–0.91, P=0.014) and those with tumor of mediatinum origin (AOR=0.58, 95% CI=0.34–0.99, P=0.044). When the protective genotypes were combined, we observed that subjects harboring 3 protective genotypes had a significant lower neuroblastoma risk than those with 0–2 protective genotypes among the following subgroup: age >18 months (AOR=0.33, 95% CI=0.14–0.78, P=0.012), male (AOR=0.18, 95% CI=0.06–0.60, P=0.005), tumor of adrenal gland-origin (AOR=0.31, 95% CI=0.09–0.99, P=0.048) and early-stage tumor (AOR=0.28, 95% CI=0.10–0.79, P=0.016).

**HMGA2 Haplotypes and Neuroblastoma Risk**

As shown in Table 3, eight haplotypes were observed in the studied subjects. In comparison with the reference haplotype GAT, a significant association was observed
Table 1 Association Between HMGA2 Gene Polymorphisms and Neuroblastoma Risk

| Genotype | Cases (N=505) | Controls (N=1070) | P a | Crude OR (95% CI) | P b | Adjusted OR (95% CI) | P b |
|----------|---------------|-------------------|-----|------------------|-----|---------------------|-----|
| rs6581658 A>G (HWE=0.365) | | | | | | | |
| AA      | 319 (63.17)   | 666 (62.24) | 1.00 | | 1.00 | | |
| AG      | 158 (31.29)   | 350 (32.71) | 0.98 (0.80–1.21) | 0.860 | 0.98 (0.79–1.21) | 0.839 |
| GG      | 28 (5.54)     | 54 (5.05)     | 1.13 (0.71–1.80) | 0.615 | 1.12 (0.71–1.79) | 0.622 |
| Additive|   |           | 0.893 | 0.99 (0.83–1.18) | 0.894 | 0.99 (0.83–1.18) | 0.899 |
| Dominant| 186 (36.83)   | 404 (37.76)  | 0.96 (0.77–1.20) | 0.724 | 0.96 (0.77–1.20) | 0.729 |
| Recessive| 477 (94.46)   | 1016 (94.95) | 1.10 (0.69–1.77) | 0.678 | 1.11 (0.69–1.77) | 0.676 |
| rs8756 A>C (HWE=0.811) | | | | | | | |
| AA      | 425 (84.16)   | 854 (79.81)  | 1.00 | | 1.00 | | |
| AC      | 76 (15.05)    | 203 (18.97)  | 0.79 (0.60–1.05) | 0.100 | 0.79 (0.60–1.04) | 0.093 |
| CC      | 4 (0.79)      | 13 (1.21)    | 0.65 (0.21–2.00) | 0.454 | 0.64 (0.21–1.98) | 0.439 |
| Additive|   |           | 0.038 | 0.76 (0.58–0.99) | 0.038 | 0.76 (0.58–0.99) | 0.038 |
| Dominant| 80 (15.84)    | 216 (20.19)  | 0.039 | 0.74 (0.56–0.99) | 0.040 | 0.74 (0.56–0.99) | 0.039 |
| Recessive| 501 (99.21)   | 1057 (98.79) | 0.448 | 0.65 (0.21–2.00) | 0.452 | 0.65 (0.21–1.99) | 0.447 |
| rs968697 T>C (HWE=0.780) | | | | | | | |
| TT      | 390 (77.23)   | 799 (74.67)  | 1.00 | | 1.00 | | |
| TC      | 107 (21.19)   | 250 (23.36)  | 0.92 (0.72–1.17) | 0.488 | 0.92 (0.72–1.17) | 0.474 |
| CC      | 8 (1.58)      | 21 (1.96)    | 0.82 (0.36–1.85) | 0.628 | 0.84 (0.37–1.90) | 0.666 |
| Additive|   |           | 0.258 | 0.88 (0.70–1.10) | 0.259 | 0.88 (0.70–1.10) | 0.266 |
| Dominant| 115 (22.77)   | 271 (25.33)  | 0.271 | 0.87 (0.68–1.12) | 0.272 | 0.87 (0.68–1.12) | 0.276 |
| Recessive| 497 (98.42)   | 1049 (98.04) | 0.602 | 0.80 (0.35–1.83) | 0.603 | 0.81 (0.36–1.85) | 0.622 |

Combined effect of protective genotypes c

| 0     | 14 (2.77)     | 27 (2.52)    | 1.00 | 1.00 | |
| 1     | 320 (63.37)   | 641 (59.91)  | 0.96 (0.50–1.86) | 0.910 | 0.96 (0.50–1.86) | 0.901 |
| 2     | 161 (31.88)   | 344 (32.15)  | 0.90 (0.46–1.77) | 0.765 | 0.90 (0.46–1.77) | 0.763 |
| 3     | 10 (1.98)     | 58 (5.42)    | 0.33 (0.13–0.84) | 0.021 | 0.33 (0.13–0.84) | 0.020 |
| 0–2   | 495 (98.02)   | 1012 (94.58) | 0.002 | 0.35 (0.18–0.70) | 0.003 | 0.35 (0.18–0.70) | 0.003 |
| 3     | 10 (1.98)     | 58 (5.42)    |   |   | | |

Notes: The results were in bold, if the 95% CI excluded 1 or P<0.05. a χ² test for genotype distributions between neuroblastoma patients and cancer-free controls.

b Adjusted for age and gender. c Risk genotypes were rs6581658 AA/AG, rs8756 AC/CC and rs968697 TC/CC

Abbreviations: OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.

Discussion

We conducted this four-center case-control study to investigate the association between HMGA2 gene polymorphisms and neuroblastoma susceptibility. Here, we found that rs8756 AC/CC genotypes could reduce the risk of neuroblastoma, especially among subgroups with age > 18 months, male, and subjects with the mediastinum-origin tumor. To the best of our knowledge, the current study is the first investigation to explore the association between HMGA2 polymorphisms and neuroblastoma risk in the Chinese population.

HMGA2, as one of the major nonhistone chromosomal proteins, has been implicated in many fundamental cellular processes, including gene regulation, cell cycle, differentiation, and viral integration.47 This chromatin-associated protein binds to AT-rich DNA sequences and potentiates the effects of transcription factors by altering local chromatin structure. Monzen et al demonstrate that HMGA2 cooperated with the Smad transcription factor to induce the expression of Nkx2.5, which encodes an important early transcription factor for cardiac development. This is accomplished through HMGA2’s binding to the conserved AT-rich region in the Nkx2.5 promoter. The knockdown of HMGA2 blocks cardiomyocyte differentiation in an embryonal carcinoma cell line and completely abrogates

for the haplotype ACC (AOR=0.36, 95% CI=0.18–0.72, P=0.004).
Table 2 Stratification Analysis for Association Between HMGA2 Gene Genotypes and Neuroblastoma Susceptibility

| Variables               | rs8756 (Case/Control) | OR (95% CI) | P   | AOR (95% CI)* | P* | OR (95% CI) | P | AOR (95% CI)* | P* |
|-------------------------|-----------------------|-------------|-----|---------------|----|-------------|---|---------------|----|
|                         | AA        | AC/CC       |     |               |    | AA          |   |               |    |
| Age, month              | ≤18       | 155/344     | 34/81| 0.93 (0.60–1.45) | 0.754 | 0.94 (0.60–1.46) | 0.772 | 185/403 | 4/22 | 0.40 (0.14–1.17) | 0.093 | 0.40 (0.14–1.18) | 0.097 |
|                         | >18       | 270/510     | 46/135| 0.64 (0.45–0.93) | 0.018 | 0.65 (0.45–0.93) | 0.020 | 310/609 | 6/36 | 0.33 (0.14–0.79) | 0.012 | 0.33 (0.14–0.78) | 0.012 |
| Gender                  | Female    | 176/366     | 37/82| 0.94 (0.61–1.44) | 0.771 | 0.94 (0.61–1.44) | 0.767 | 206/423 | 7/25 | 0.58 (0.25–1.35) | 0.205 | 0.57 (0.24–1.35) | 0.202 |
|                         | Male      | 249/488     | 43/134| 0.63 (0.43–0.92) | 0.016 | 0.63 (0.43–0.91) | 0.014 | 289/589 | 3/33 | 0.19 (0.06–0.61) | 0.006 | 0.18 (0.06–0.60) | 0.005 |
| Sites of origin         | Adrenal gland | 145/854   | 28/216| 0.76 (0.50–1.18) | 0.220 | 0.76 (0.49–1.17) | 0.206 | 170/1012 | 3/58 | 0.31 (0.10–0.99) | 0.049 | 0.31 (0.09–0.99) | 0.048 |
|                         | Retroperitoneal | 124/854 | 23/216| 0.73 (0.46–1.17) | 0.196 | 0.73 (0.46–1.17) | 0.191 | 145/1012 | 2/58 | 0.24 (0.06–0.996) | 0.049 | 0.24 (0.06–1.01) | 0.052 |
|                         | Mediastinum | 118/854   | 17/216| 0.57 (0.34–0.97) | 0.037 | 0.58 (0.34–0.99) | 0.044 | 133/1012 | 2/58 | 0.26 (0.06–1.09) | 0.065 | 0.26 (0.06–1.08) | 0.063 |
|                         | Others    | 32/854     | 10/216| 1.24 (0.60–2.55) | 0.568 | 1.25 (0.60–2.58) | 0.554 | 41/1012 | 1/58 | 0.43 (0.06–3.15) | 0.403 | 0.43 (0.06–3.18) | 0.408 |
| Clinical stage          | I+II+IV   | 208/854    | 42/216| 0.80 (0.56–1.15) | 0.225 | 0.81 (0.56–1.16) | 0.248 | 246/1012 | 4/58 | 0.28 (0.10–0.79) | 0.016 | 0.28 (0.10–0.79) | 0.016 |
|                         | III+IV    | 195/854    | 37/216| 0.75 (0.51–1.10) | 0.140 | 0.74 (0.51–1.09) | 0.128 | 226/1012 | 6/58 | 0.46 (0.20–1.09) | 0.077 | 0.46 (0.20–1.09) | 0.077 |

Notes: The results were in bold, if the 95% CI excluded 1 or P<0.05. *Adjusted for age and gender, omitting the corresponding stratify factor.

Abbreviations: AOR, adjusted odds ratio; CI, confidence interval.
Dong et al proved that the interaction between gene could also modify UTR of gene. Contributed to HMGA2 could be directly associated with the UTR polymorphism in Our results showed that rs8756 and inhibit its expression, then inhibit And one research performed by gene, was related to the reduced susceptibility Bcl-2 gene were investigated; more potent- could act on the 3′ A l k a y y a l ie t a l f o u n d HMGA2 HMGA2 UTR of the HMGA2 HMGA2 miR-495 miR-495 ʹ These gene and neuroblastoma HMGA2 HMGA2 polymorphism rs1042725 by E2F1, which exert critical effects on the miR-490-3p is UTR plays a direct let-7 41 A recent study con- Gene Based on Observed Genotypes and Their Association with the

| Haplotypes* | Cases (n=1010) | Controls (n=2140) | Crude OR (95% CI) | P  | Adjusted ORb (95% CI) | pb |
|------------|----------------|------------------|------------------|----|----------------------|----|
| GAT        | 199 (19.70)    | 416 (19.44)      | 1.00             |    | 1.00                 |    |
| GAC        | 6 (0.59)       | 12 (0.56)        | 1.05 (0.39–2.84) |    | 0.923                | 1.06 (0.39–2.86) | 0.911 |
| GCT        | 8 (0.79)       | 28 (1.31)        | 0.60 (0.27–1.34) |    | 0.213                | 0.60 (0.27–1.34) | 0.210 |
| GCC        | 1 (0.10)       | 2 (0.09)         | 1.05 (0.10–11.65) |    | 0.968                | 1.07 (0.10–11.92) | 0.954 |
| AAT        | 615 (60.89)    | 1263 (59.02)     | 1.02 (0.84–1.24) |    | 0.820                | 1.02 (0.84–1.24) | 0.824 |
| AAC        | 106 (10.50)    | 220 (10.28)      | 1.01 (0.76–1.35) |    | 0.935                | 1.01 (0.76–1.35) | 0.927 |
| ACT        | 65 (6.44)      | 141 (6.59)       | 0.97 (0.69–1.36) |    | 0.852                | 0.97 (0.69–1.36) | 0.849 |
| ACC        | 10 (0.99)      | 58 (2.71)        | 0.36 (0.18–0.72) |    | 0.004                | 0.36 (0.18–0.72) | 0.004 |

Notes: The results were in bold, if the 95% CI excluded 1 or P<0.05. *The haplotypes order were rs6581658, rs8756 and rs968697. Obtained in logistic regression models with adjustment for age and gender.

Abbreviations: OR, odds ratio; CI, confidence interval.

in vivo cardiogenesis in embryos of the frog Xenopus laevis. Dong et al proved that the interaction between HMGA2 and pRb facilitated the transcriptional activation of FOXL2 by E2F1, which exert critical effects on the metastases and EMT of chemo-resistant gastric cancer. Further studies confirmed that HMGA2 could also modify the expression of Bcl-2, EMT-associated proteins, and caspase activity, indicating that HMGA2 plays a direct role in regulating cell apoptosis and EMT.

Here, our research data showed that rs8756 A>C, one SNP located at 3′ untranslated region (UTR) of the HMGA2 gene, was related to the reduced susceptibility of neuroblastoma. It should be noted that HMGA2 is a functional target of several microRNAs, which target the 3′UTR of genes for degradation. Yu et al found that miRNA let-7 could reduce breast carcinoma cells proliferation and self-renewal partly by posttranscriptional regulation of HMGA2. And one research performed by Kang et al indicated miR-490-3p could act on the 3′ UTR of HMGA2 and inhibit its expression, then inhibit the proliferation, invasion, migration, and EMT of esophageal squamous cell carcinoma cells. A recent study confirmed that miR-495 could be directly associated with the 3′ UTR of HMGA2. Upregulated expression of miR-495 significantly downregulated the mRNA and protein expression levels of HMGA2 in A549 cells, and then suppressed the proliferation of lung cancer cells. These above studies all indicated that miRNA is an important regulatory mechanism for the expression of HMGA2. It is reasonable to speculate that the rs8756 A>C in the 3′ UTR of the HMGA2 gene may affect some miRNA’s binding to HMGA2, thereby altering gene expression level.

This was the first research to investigate the association between SNPs in the HMGA2 gene and neuroblastoma susceptibility. However, the relationship between HMGA2 polymorphisms and other complex human diseases has been explored, such as nanism. Bouatia-Naji et al showed that rs1042725 in the 3′ UTR of the HMGA2 gene contributed to height variability in European populations. Kuipers et al further demonstrated that HMGA2 polymorphism rs1042725 may be involved in bone metabolism; A novel association between rs1042725 and trabecular bone mineral density in ethnically diverse older men was suggested. Further study by Hendriks et al indicated that rs1042725 is not only associated with height variation in the general population but also plays an important role in one of the extremes of the height distribution. Alkayyali et al found HMGA2 rs1531343 polymorphism was associated with increased risk of developing nephropathy in patients with type 2 diabetes. Moreover, another 3′ UTR polymorphism in HMGA2, rs8756 was shown to be associated with human stature in an Icelandic population. Our results showed that rs8756 A>C polymorphism was associated with neuroblastoma susceptibility. The rs8756 C allele exerted protective effects against neuroblastoma. However, the other two SNPs rs6581658 A>G and rs968697 T>C were not associated with neuroblastoma risk. These results should be further validated by the well-designed studies with larger sample size.

Limitations of the current study should be notified. First, selection bias is inevitable as it is a hospital-based case-control study. Second, even we enrolled participants from four independent hospitals, the sample size is still relatively small, especially for the stratified analysis. The statistical power might be compromised. Third, only three SNPs in the HMGA2 gene were investigated; more potentially functional polymorphisms in the HMGA2 gene should be assessed in the future study. Fourth, impacts of
Conclusions
In summary, we firstly provide evidence that polymorphism in the HMGA2 gene could affect neuroblastoma risk. The HMGA2 rs8756 AC/CC genotypes are associated with decreased neuroblastoma susceptibility. It suggests that HMGA2 gene polymorphisms might be potential biomarkers for neuroblastoma susceptibility.

Acknowledgments
This study was supported by grants from the Pearl River S&T Nova Program of Guangzhou (No: 201710010086) and Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease (No: 2019B030301004), and National Natural Science Foundation of China (No: 81602666). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Capasso M, Diskin SJ. Genetics and genomics of neuroblastoma. Cancer Treat Res. 2010;155:65–84.
2. Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol. 1997;19(5):428–432. doi:10.1097/00004342-199709000-00004
3. Bao PP, Li K, Wu CX, et al. [Recent incidences and trends of childhood malignant solid tumors in Shanghai, 2002–2010]. Zhonghua Er Ke Za Zhi. 2013;51(4):288–294.
4. He J, Xia H. [Experiences and dilemmas of multi-center studies on neuroblastoma]. J Clin Pediatr Surg. 2019;18(1):9–12.
5. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28(15):2625–2634. doi:10.1200/JCO.2009.27.0421
6. Delgado DC, Hank JA, Kolesar J, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010;70(23):9554–9561. doi:10.1158/0008-5472.CAN-10-2211
7. Hero B, Simon T, Spitz R, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008;26(9):1504–1510. doi:10.1200/JCO.2007.12.3349
8. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol. 2009;27(7):1007–1013. doi:10.1200/JCO.2007.13.8925
9. Laverride C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2009;101(16):1131–1140. doi:10.1093/jnci/djp230
10. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev. 2010;36(4):277–285. doi:10.1016/j.ctrv.2010.02.003
11. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106–2120. doi:10.1016/S0140-6736(07)60983-0
12. Bourdeaut F, Trochet D, Janoueix-Lerosey I, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Cancer Lett. 2005;228(1–2):51–58. doi:10.1016/j.canlet.2005.01.055
13. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930–935. doi:10.1038/nature07261
14. De Roos AJ, Olshan AF, Teschke K, et al. Parental occupational exposures to chemicals and incidence of neuroblastoma in offspring. Am J Epidemiol. 2001;154(2):106–114.
15. De Roos AJ, Teschke K, Savitz DA, et al. Parental occupational exposures to electromagnetic fields and radiation and the incidence of neuroblastoma in offspring. Epidemiology. 2001;12(5):508–517. doi:10.1097/00001548-200109000-00008
16. Patton T, Olshan AF, Neglia JP, Castleberry RP, Smith J. Parental exposure to medical radiation and neuroblastoma in offspring. Paediatr Perinat Epidemiol. 2004;18(3):178–185. doi:10.1111/j.1365-2141.2004.003
17. Han W, Zhou Y, Zhong R, et al. Functional polymorphisms in FAS/ FASL system increase the risk of neuroblastoma in Chinese population. PLoS One. 2013;8(8):e71656. doi:10.1371/journal.pone.0071656
18. Capasso M, Diskin S, Cimmino F, et al. Common genetic variants in NEFL influence gene expression and neuroblastoma risk. Cancer Res. 2014;74(23):6913–6924. doi:10.1158/0008-5472.CAN-14-0431
19. Oldridge DA, Wood AC, Weichert-Leuehy N, et al. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature. 2015;528(7582):418–421. doi:10.1038/nature15540
20. Standler ZK, Vijai J, Thom P, et al. Genome-wide association studies of cancer predisposition. Hematol Oncol Clin North Am. 2010;24(5):973–996. doi:10.1016/j.hoc.2010.06.009
21. Maris JM, Mosse YP, Bradford JP, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008;358(24):2585–2593. doi:10.1056/NEJMoa0708698
22. Capasso M, Devoto M, Hou C, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009;41(6):718–723. doi:10.1038/ng.374
23. Nguyen Le B, Diskin SJ, Capasso M, et al. Phenotype restricted genome-wide association studies using a gene-centric approach identifies three low-risk neuroblastoma susceptibility loci. PLoS Genet. 2011;7(3):e1002026. doi:10.1371/journal.pgen.1002026
24. Wang K, Diskin SJ, Zhang H, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 2011;469(7329):216–220. doi:10.1038/nature09609
25. Diskin SJ, Capasso M, Schnepp RW, et al. Common variation at 6q16 within HACE1 and LIN2NB influences susceptibility to neuroblastoma. Nat Genet. 2012;44(10):1126–1130. doi:10.1038/ng.2387
26. McDaniel LD, Conkrite KL, Chang X, et al. Common variants upstream of MLF1 at 3q25 and within CPZ at 4p16 associated with neuroblastoma. PLoS Genet. 2017;13(5):e1006787. doi:10.1371/journal.pgen.1006787
27. Cimmino F, Avitabile M, Diskin SJ, et al. Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor. Int J Cancer. 2018;143(11):2828–2837. doi:10.1002/ijc.31413
28. Capasso M, McDaniel LD, Cimmino F, et al. The functional variant rs34330 of CDKNB1 is associated with risk of neuroblastoma. J Cell Mol Med. 2017;21(12):3224–3230. doi:10.1111/jcmm.2017.21.issue-12
29. Lee JY, Kong G. Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression. Cell Mol Life Sci. 2016;73 (24):4643–4660. doi:10.1007/s00018-016-2313-z
30. Shang Y, Cai X, Fan D. Roles of epithelial-mesenchymal transition in cancer drug resistance. Curr Cancer Drug Targets. 2013;13 (9):915–929. doi:10.2174/15680066136660097
31. Wu J, Liu Z, Shao C, et al. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res. 2011;71(2):349–359. doi:10.1158/0008-5472.CAN-10-2550
32. Li Y, Zhao Z, Xu C, Zhou Z, Zhu Z, You T. HMGA2 induces transcription factor Slug expression to promote epithelial-to-mesenchymal transition and contributes to colon cancer progression. Cancer Lett. 2014;355(1):130–140. doi:10.1016/j.canlet.2014.09.007
33. Hammond SM, Sharpless NE. HMGA2, microRNAs, and stem cell aging. Cell. 2008;135(6):1013–1016. doi:10.1016/j.cell.2008.11.026
34. Pfannkuche K, Sumner H, Li O, Hescheler J, Droge P. The high mobility group protein HMGA2: a co-regulator of chromatin structure and pluripotency in stem cells? Stem Cell Rev. 2005;1(3):224–230. doi:10.1017/s120005-009-0978-y
35. Fedele M, Visone R, De Martino I, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell. 2006;9 (6):459–471. doi:10.1016/j.ccr.2006.04.024
36. Sarhadi VK, Wikman H, Salmenkivi K, et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol. 2006;209 (2):206–212. doi:10.1002/(ISSN)1096-9096
37. Dangi-Garimella S, Krantz SB, Barron MR, et al. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 2011;71(3):1019–1028. doi:10.1158/0008-5472.CAN-10-1855
38. Wang X, Liu X, Li AY, et al. Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res. 2011;17(8):2570–2580. doi:10.1158/1078-0432.CCR-10-2542
39. Weedo MN, Lette G, Freathy RM, et al. A common variant of HMGA2 is associated with adult and childhood height in the general population. Nat Genet. 2007;39(10):1245–1250. doi:10.1038/ng.2121
40. Kuipers A, Zhang Y, Cauley JA, et al. Association of a high mobility group gene (HMGA2) variant with bone mineral density. Bone. 2009;45(2):295–300. doi:10.1016/j.bone.2009.04.197
41. Alkayyal S, Lajer M, Deshmukh H, et al. Common variant in the HMGA2 gene increases susceptibility to nephropathy in patients with type 2 diabetes. Diabetologia. 2013;56(2):323–329. doi:10.1007/s00125-012-2760-5
42. Cheng J, Zhao Z, Xin Y, et al. Relevance of XPD polymorphisms to neuroblastoma risk in Chinese children: a four-center case-control study. Aging (Albany NY). 2018;10(8):1989–2000. doi:10.18632/aging.101522
43. He J, Wang F, Zhu J, et al. Association of potentially functional variants in the XPG gene with neuroblastoma risk in a Chinese population. J Cell Mol Med. 2016;20(8):1481–1490. doi:10.1111/jcmm.2016.20.issue-8
44. He J, Qu L, Wang MY, et al. Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet. 2012;131 (7):1235–1244. doi:10.1007/s00439-012-1152-8
45. Chen X, Wang Y, Chen X, et al. Genetic variants in the regulatory region of SLC10A1 are not associated with the risk of hepatitis B virus infection and clearance. Infect Genet Evol. 2016;44:495–500. doi:10.1016/j.igev.2016.07.043
46. Chang J, Zhong R, Tian J, et al. Exome-wide analyses identify low-frequency variant in CYP26B1 and additional coding variants associated with esophageal squamous cell carcinoma. Nat Genet. 2018;50(3):338–343. doi:10.1038/s41588-018-0045-8
47. Reeves R. Molecular biology of HMG A: hubs of nuclear function. Gene. 2001;277(1–2):63–81. doi:10.1016/s0378-1119(01)00689-8
48. Monzen K, Ito Y, Naito AT, et al. A crucial role of a high mobility group protein HMGA2 in cardiogenesis. Nat Cell Biol. 2008;10 (5):567–574. doi:10.1038/ncb1719
49. Dong J, Wang R, Ren G, et al. HMGA2-FOXL2 axis regulates metastases and epithelial-to-mesenchymal transition of chemoresistant gastric cancer. Clin Cancer Res. 2017;23(13):3461–3473. doi:10.1158/1078-0432.CCR-16-2180
50. Gao X, Dai M, Li Q, Wang Z, Lu Y, Song Z. HMGA2 regulates lung cancer proliferation and metastasis. Thorac Cancer. 2017;8 (5):501–510. doi:10.1111/tea.2017.8.issue-5
51. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–1123. doi:10.1016/j.cell.2007.10.054
52. Kang NN, Ge SL, Zhang RQ, Huang YL, Liu SD, Wu KM. MiR-490-3p inhibited the proliferation and metastasis of esophageal squamous cell carcinoma by targeting HMGA2. Eur Rev Med Pharmacol Sci. 2018;22(23):8298–8305. doi:10.26355/eurev.201812_16527
53. Sun J, Qiao Y, Song T, Wang H. MiR-495 suppresses cell proliferation by directly targeting HMGA2 in lung cancer. Mol Med Rep. 2019;19 (3):1463–1470. doi:10.3892/mmr.2018.9773
54. Bouatia-Naji N, Marchand M, Cavalcanti-Proenca C, et al. Smallness for gestational age interacts with high mobility group A2 gene genetic variation to modulate height. Eur J Endocrinol. 2009;160 (4):557–560. doi:10.1530/EJE-08-0794
55. Hendriks AE, Brown MR, Boot AM, Oostra BA, Drop SL, Parks JS. Genetic variation in candidate genes like the HMGA2 gene in the European population. Hum Genet. 2008;123(6):574–583. doi:10.1007/s00439-008-0689-8
56. Gudbjartsson DF, Walters GB, Thorleifsson G, et al. Many sequence genetic variation to modulate height. Eur J Endocrinol. 2009;160 (4):557–560. doi:10.1530/EJE-08-0794
57. Hendriks AE, Brown MR, Boot AM, Oostra BA, Drop SL, Parks JS. Genetic variation in candidate genes like the HMGA2 gene in the European population. Hum Genet. 2008;123(6):574–583. doi:10.1007/s00439-008-0689-8
